{
    "nctId": "NCT00074269",
    "briefTitle": "Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer",
    "officialTitle": "Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Number of Participants With Adverse Events",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Metastatic disease\n* Meets 1 of the following criteria:\n\n  * Chemotherapy-unresponsive disease defined as 1 of the following:\n\n    * Less than a partial response to 2 consecutive chemotherapy regimens that included an anthracycline and a taxane in combination or succession\n    * Progression of disease during or within 3 months of completion of a taxane, anthracycline, or platinol-based regimen\n  * Histologically confirmed tumor involvement on bone marrow biopsy\n* Measurable or evaluable disease\\* defined as the following:\n\n  * Bidimensionally reproducible measurable mass by physical examination, ultrasonography, radiography, CT scan, or MRI\n  * Evaluable lesions apparent on clinical exam, x-ray, CT scan, or MRI which do not fit the criteria for measurability (e.g., ill-defined post-surgical masses or masses assessable in 1 dimension only)\n\n    * Elevation of biological markers (e.g., CA 27.29) is considered evaluable disease NOTE: \\*Bone lesions or pleural or peritoneal effusion alone are not considered measurable or evaluable disease\n* Appropriate candidate for allogeneic stem cell transplantation\n* No active CNS metastases\n* Available HLA-identical sibling donor\n\n  * 6/6 antigen match\n  * Donor CD34 cells at least 2 times 10\\^6/kg recipient weight\n* Hormone receptor status:\n\n  * Estrogen receptor negative or positive\n\n    * Estrogen receptor positive tumors must demonstrate progression on at least 1 hormonal manipulation\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 to 60\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Karnofsky 70-100% OR\n* ECOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* WBC at least 1,500/mm\\^3\n* Platelet count at least 30,000/mm\\^3\n\nHepatic\n\n* Bilirubin less than 3 times normal\\*\n* AST and ALT less than 3 times normal\\* NOTE: \\*Unless abnormality due to malignancy\n\nRenal\n\n* Creatinine no greater than 1.6 mg/dL\n\nCardiovascular\n\n* LVEF greater than 40% by echocardiography or MUGA\n* No myocardial infarction within the past 6 months\n\nPulmonary\n\n* DLCO greater than 40% of predicted\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* HIV negative\n* No serious localized or systemic infection\n* No hypersensitivity to E. coli-derived products\n* No history of non-breast malignant disease within the past 5 years except completely excised nonmelanoma skin cancer or carcinoma in situ of the cervix\n* No chronic inflammatory disorder requiring concurrent glucocorticosteroids or other immunosuppressive medication\n* No psychological condition or social situation that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* See Disease Characteristics\n\nEndocrine therapy\n\n* No concurrent glucocorticoids\n\nRadiotherapy\n\n* No prior radiotherapy to an indicator lesion unless the lesion shows evidence of progression after discontinuation of the therapy\n\nSurgery\n\n* Not specified\n\nOther\n\n* No concurrent immunosuppressive medication",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}